Erbitux cetuximab: Phase III data

The open-label, international Phase III NORDIC VII trial in 566 patients showed that there were no significant differences between first-line treatment with 5-fluorouracil (5-FU), folinate and oxaliplatin (FLOX) chemotherapy alone or in combination with Erbitux in ORR, PFS or OS. Furthermore, there were no significant differences between treatment arms in subgroups of patients with mutant and wild-type K-Ras genes. Data were presented at the European Society for Medical Oncology meeting in Milan. ...